Medicines Development for Global Health has received AU$1.5 million from the Australian Tropical Medicines Commercialisation fund with matching funding from the Global Health Investment Fund for a total of AU$ 3 million to used to run a pivotal Phase II dose finding trial for moxidectin for scabies elimination.

For more information, please see MDL press release.